Core Laboratories Inc.
Rank #374ValueCLB · NYSE · Energy
Core Laboratories Inc. (CLB) — Rank #374 by gross profitability (GP/assets 0.19) · ROE 10.9% · Piotroski F-Score 7 / 9.
As-of 2026-09-15 · CIK 0001958086 · all metrics point-in-time as of the filing date.
About
Core Laboratories Inc. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally.
Show moreShow less
It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and natural gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies, as well as services that support carbon capture, utilization and storage, geothermal projects, and the evaluation and appraisal of mining activities. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, production, and well abandonment. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. The company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. Core Laboratories Inc.
was founded in 1936 and is based in Houston, Texas.
- Industry
- Oil & Gas Equipment & Services
- Sector
- Energy
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- corelab.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-03-23 | 2024-12-31filed 2025-02-13 | 2023-12-31filed 2024-02-15 | 2022-12-31filed 2024-02-15 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 14.6 | 15.0 | 15.8 | 17.2 |
| Stock-based compensation | 7.1 | 3.8 | 14.0 | 7.8 |
| Change in receivables | 5.0 | 3.6 | 2.6 | 10.1 |
| Change in inventory | (2.6) | (9.4) | 13.0 | 14.9 |
| Change in payables | 0.5 | 0.5 | (12.9) | 15.4 |
| Operating cash flow | 37.0 | 56.4 | 24.8 | 25.0 |
| Investing | ||||
| Capital expenditures | 11.2 | 13.0 | 10.6 | — |
| Acquisitions, net of cash | 1.2 | — | — | — |
| Investing cash flow | (2.2) | (6.4) | (6.7) | (3.9) |
| Financing | ||||
| Debt issued | 48.0 | 44.0 | 202.0 | 116.0 |
| Debt repaid | 63.0 | 82.0 | 211.0 | 131.0 |
| Share repurchases | 12.4 | 5.3 | 2.2 | 3.9 |
| Dividends paid | 1.9 | 1.9 | 1.9 | 1.9 |
| Financing cash flow | (31.3) | (46.0) | (18.4) | (23.4) |
| Summary | ||||
| Free cash flow | 25.8 | 43.4 | 14.2 | 14.2 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?